News

Hosted on MSN5mon
FDA approves Johnson & Johnson’s nasal spray for depression as stand-alone treatment
The Food and Drug Administration approved Johnson & Johnson's nasal spray to be used alone in adults with a major depressive disorder that is difficult to treat, as sales of the drug grow.
UPI5mon
FDA approves Spravato, first monotherapy nasal spray to treat depression - UPI
Johnson & Johnson's Spravato was approved to treat a major depressive disorder, or MDD, in adults. The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat ...
Popular Science5mon
FDA approves first-of-its-kind nasal spray for severe depression
Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the standalone treatment of major depressive disorder (MDD), PTSD, and ...
Forbes6y
FDA Approves Johnson & Johnson’s Ketamine-Derived Drug For Treatment-Resistant Depression
FDA Approves Johnson & Johnson’s Ketamine-Derived Drug For ... The U.S. Food & Drug Administration Tuesday approved Johnson & Johnson’s ketamine-derived nasal spray Spravato for treatment ...
NPR6y
FDA Approves Esketamine Nasal Spray For Hard-To-Treat Depression
Esketamine, developed by Johnson & Johnson, will be administered as a nasal spray and be used in conjunction with an oral antidepressant. It will be marketed under the brand name Spravato .
ConsumerAffairs5mon
FDA approves nasal spray drug to treat depression - ConsumerAffairs
Johnson & Johnson has announced that the U.S. Food and Drug Administration has approved the nasal spray Spravato as a treatment for severe depression. FDA approves nasal spray drug to treat depression ...
Newsweek5mon
FDA Approves Nasal Spray for Depression - Newsweek
FDA Approves Nasal Spray for Depression. Published Jan 22, 2025 at 5:22 AM EST Updated Jan 22, 2025 at 6:12 AM EST. By . ... the manufacturer Johnson & Johnson said in a press release.
CNN5mon
FDA approves standalone use of J&J’s ketamine-derived depression treatment - CNN
The U.S. Food and Drug Administration expanded approval for Johnson & Johnson’s nasal spray, Spravato, to allow it to be used as a standalone treatment for patients with severe depression, the ...
KSAT5mon
FDA approves first nasal spray for major depression disorder - KSAT.com
The nasal spray targets glutamate, the most abundant excitatory neurotransmitter in the brain, according to Johnson & Johnson. If you are interested in taking SPRAVATO, it is recommended you talk ...
NPR5mon
FDA allows standalone use of nasal spray antidepressant Spravato (esketamine) : Shots - Health News : NPR
The U.S. Food and Drug Administration has expanded its approval of Spravato, an antidepressant nasal spray. The drug is now cleared for use as a standalone treatment for depression. Spravato is ...
CBS News6y
FDA approves form of ketamine for depression treatment
FDA approves ketamine nasal spray to treat depression 00:43. The Food and Drug Administration on Tuesday approved a form of ketamine, which is a rapid acting anesthetic that has been used ...